Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid

Mario Fracchia, Kenneth D R Setchell, Andrea Crosignani, Mauro Podda, Nancy O'Connell, Roberto Ferraris, Alan F. Hofmann, Giovanni Galatola

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The efficiency of bile acid conjugation before and during therapy with 600 mg/day of ursodeoxycholic acid was measured in seven adult patients with early chronic cholestatic liver disease (6 with primary biliary cirrhosis; 1 with primary sclerosing cholangitis). Duodenal bile samples were obtained by aspiration and the proportion of unconjugated bile acids was determined using lipophilic anion exchange chromatography to separate bile acid classes, followed by analysis of individual bile acids by gas chromatography-mass spectrometry. The proportion of conjugated bile acids was determined by high-performance liquid chromatography. Use of a 99mTc-HIDA recovery marker permitted the absolute mass of unconjugated bile acids in the gallbladder to be calculated. Unconjugated bile acids comprised 0.4% of total biliary bile acids before and 0.2% during ursodeoxycholic acid therapy, indicating highly efficient conjugation of bile acids. During therapy, percentage unconjugated ursodeoxycholic acid significantly increased from (mean ± S.D.) 13 ± 13% to 54 ± 12%; P <0.002. When the unconjugated and conjugated fractions of bile acids were compared, there was an enrichment in unconjugated fraction for cholic acid and ursodeoxycholic acid and a depletion for chenodeoxycholic acid both in basal condition and during ursodeoxycholic acid therapy, suggesting that hydrophilic bile acids were conjugated less efficiently. During therapy, the conjugation efficiency significantly increased for cholic acid and ursodeoxycholic acid. The pretreatment mass of total unconjugated bile acids in the gallbladder was (mean ± S.D.) 4.4 ± 3.2 μmol, and was not significantly changed by ursodeoxycholic acid therapy (6.2 ± 3.5 μmol). However, ursodeoxycholic acid therapy caused a significant increase in the mass of unconjugated ursodeoxycholic acid. It is concluded that endogenous bile acids and exogenous ursodeoxycholic acid when given at the usual dose are efficiently conjugated in patients with early cholestatic liver disease. Despite showing increased biliary unconjugated ursodeoxcholic acid during its oral administration, our data do not lend support to the occurrence of hypercholeresis due to cholehepatic shunting of bile acids.

Original languageEnglish
Pages (from-to)175-185
Number of pages11
JournalClinica Chimica Acta
Volume248
Issue number2
DOIs
Publication statusPublished - Apr 30 1996

Fingerprint

Ursodeoxycholic Acid
Bile Acids and Salts
Liver
Liver Diseases
Therapeutics
Cholic Acid
Gallbladder
Technetium Tc 99m Lidofenin
Chenodeoxycholic Acid
Sclerosing Cholangitis
Biliary Liver Cirrhosis
High performance liquid chromatography
Chromatography
Bile
Gas chromatography
Gas Chromatography-Mass Spectrometry

Keywords

  • bile acid conjugation efficiency
  • cholehepatic shunting
  • cholestasis
  • primary biliary cirrhosis
  • primary sclerosing cholangitis
  • unconjugated bile acids
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid. / Fracchia, Mario; Setchell, Kenneth D R; Crosignani, Andrea; Podda, Mauro; O'Connell, Nancy; Ferraris, Roberto; Hofmann, Alan F.; Galatola, Giovanni.

In: Clinica Chimica Acta, Vol. 248, No. 2, 30.04.1996, p. 175-185.

Research output: Contribution to journalArticle

Fracchia, Mario ; Setchell, Kenneth D R ; Crosignani, Andrea ; Podda, Mauro ; O'Connell, Nancy ; Ferraris, Roberto ; Hofmann, Alan F. ; Galatola, Giovanni. / Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid. In: Clinica Chimica Acta. 1996 ; Vol. 248, No. 2. pp. 175-185.
@article{4ff21df2d8cf40a48c5dd4296be0f959,
title = "Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid",
abstract = "The efficiency of bile acid conjugation before and during therapy with 600 mg/day of ursodeoxycholic acid was measured in seven adult patients with early chronic cholestatic liver disease (6 with primary biliary cirrhosis; 1 with primary sclerosing cholangitis). Duodenal bile samples were obtained by aspiration and the proportion of unconjugated bile acids was determined using lipophilic anion exchange chromatography to separate bile acid classes, followed by analysis of individual bile acids by gas chromatography-mass spectrometry. The proportion of conjugated bile acids was determined by high-performance liquid chromatography. Use of a 99mTc-HIDA recovery marker permitted the absolute mass of unconjugated bile acids in the gallbladder to be calculated. Unconjugated bile acids comprised 0.4{\%} of total biliary bile acids before and 0.2{\%} during ursodeoxycholic acid therapy, indicating highly efficient conjugation of bile acids. During therapy, percentage unconjugated ursodeoxycholic acid significantly increased from (mean ± S.D.) 13 ± 13{\%} to 54 ± 12{\%}; P <0.002. When the unconjugated and conjugated fractions of bile acids were compared, there was an enrichment in unconjugated fraction for cholic acid and ursodeoxycholic acid and a depletion for chenodeoxycholic acid both in basal condition and during ursodeoxycholic acid therapy, suggesting that hydrophilic bile acids were conjugated less efficiently. During therapy, the conjugation efficiency significantly increased for cholic acid and ursodeoxycholic acid. The pretreatment mass of total unconjugated bile acids in the gallbladder was (mean ± S.D.) 4.4 ± 3.2 μmol, and was not significantly changed by ursodeoxycholic acid therapy (6.2 ± 3.5 μmol). However, ursodeoxycholic acid therapy caused a significant increase in the mass of unconjugated ursodeoxycholic acid. It is concluded that endogenous bile acids and exogenous ursodeoxycholic acid when given at the usual dose are efficiently conjugated in patients with early cholestatic liver disease. Despite showing increased biliary unconjugated ursodeoxcholic acid during its oral administration, our data do not lend support to the occurrence of hypercholeresis due to cholehepatic shunting of bile acids.",
keywords = "bile acid conjugation efficiency, cholehepatic shunting, cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis, unconjugated bile acids, ursodeoxycholic acid",
author = "Mario Fracchia and Setchell, {Kenneth D R} and Andrea Crosignani and Mauro Podda and Nancy O'Connell and Roberto Ferraris and Hofmann, {Alan F.} and Giovanni Galatola",
year = "1996",
month = "4",
day = "30",
doi = "10.1016/0009-8981(95)06252-1",
language = "English",
volume = "248",
pages = "175--185",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid

AU - Fracchia, Mario

AU - Setchell, Kenneth D R

AU - Crosignani, Andrea

AU - Podda, Mauro

AU - O'Connell, Nancy

AU - Ferraris, Roberto

AU - Hofmann, Alan F.

AU - Galatola, Giovanni

PY - 1996/4/30

Y1 - 1996/4/30

N2 - The efficiency of bile acid conjugation before and during therapy with 600 mg/day of ursodeoxycholic acid was measured in seven adult patients with early chronic cholestatic liver disease (6 with primary biliary cirrhosis; 1 with primary sclerosing cholangitis). Duodenal bile samples were obtained by aspiration and the proportion of unconjugated bile acids was determined using lipophilic anion exchange chromatography to separate bile acid classes, followed by analysis of individual bile acids by gas chromatography-mass spectrometry. The proportion of conjugated bile acids was determined by high-performance liquid chromatography. Use of a 99mTc-HIDA recovery marker permitted the absolute mass of unconjugated bile acids in the gallbladder to be calculated. Unconjugated bile acids comprised 0.4% of total biliary bile acids before and 0.2% during ursodeoxycholic acid therapy, indicating highly efficient conjugation of bile acids. During therapy, percentage unconjugated ursodeoxycholic acid significantly increased from (mean ± S.D.) 13 ± 13% to 54 ± 12%; P <0.002. When the unconjugated and conjugated fractions of bile acids were compared, there was an enrichment in unconjugated fraction for cholic acid and ursodeoxycholic acid and a depletion for chenodeoxycholic acid both in basal condition and during ursodeoxycholic acid therapy, suggesting that hydrophilic bile acids were conjugated less efficiently. During therapy, the conjugation efficiency significantly increased for cholic acid and ursodeoxycholic acid. The pretreatment mass of total unconjugated bile acids in the gallbladder was (mean ± S.D.) 4.4 ± 3.2 μmol, and was not significantly changed by ursodeoxycholic acid therapy (6.2 ± 3.5 μmol). However, ursodeoxycholic acid therapy caused a significant increase in the mass of unconjugated ursodeoxycholic acid. It is concluded that endogenous bile acids and exogenous ursodeoxycholic acid when given at the usual dose are efficiently conjugated in patients with early cholestatic liver disease. Despite showing increased biliary unconjugated ursodeoxcholic acid during its oral administration, our data do not lend support to the occurrence of hypercholeresis due to cholehepatic shunting of bile acids.

AB - The efficiency of bile acid conjugation before and during therapy with 600 mg/day of ursodeoxycholic acid was measured in seven adult patients with early chronic cholestatic liver disease (6 with primary biliary cirrhosis; 1 with primary sclerosing cholangitis). Duodenal bile samples were obtained by aspiration and the proportion of unconjugated bile acids was determined using lipophilic anion exchange chromatography to separate bile acid classes, followed by analysis of individual bile acids by gas chromatography-mass spectrometry. The proportion of conjugated bile acids was determined by high-performance liquid chromatography. Use of a 99mTc-HIDA recovery marker permitted the absolute mass of unconjugated bile acids in the gallbladder to be calculated. Unconjugated bile acids comprised 0.4% of total biliary bile acids before and 0.2% during ursodeoxycholic acid therapy, indicating highly efficient conjugation of bile acids. During therapy, percentage unconjugated ursodeoxycholic acid significantly increased from (mean ± S.D.) 13 ± 13% to 54 ± 12%; P <0.002. When the unconjugated and conjugated fractions of bile acids were compared, there was an enrichment in unconjugated fraction for cholic acid and ursodeoxycholic acid and a depletion for chenodeoxycholic acid both in basal condition and during ursodeoxycholic acid therapy, suggesting that hydrophilic bile acids were conjugated less efficiently. During therapy, the conjugation efficiency significantly increased for cholic acid and ursodeoxycholic acid. The pretreatment mass of total unconjugated bile acids in the gallbladder was (mean ± S.D.) 4.4 ± 3.2 μmol, and was not significantly changed by ursodeoxycholic acid therapy (6.2 ± 3.5 μmol). However, ursodeoxycholic acid therapy caused a significant increase in the mass of unconjugated ursodeoxycholic acid. It is concluded that endogenous bile acids and exogenous ursodeoxycholic acid when given at the usual dose are efficiently conjugated in patients with early cholestatic liver disease. Despite showing increased biliary unconjugated ursodeoxcholic acid during its oral administration, our data do not lend support to the occurrence of hypercholeresis due to cholehepatic shunting of bile acids.

KW - bile acid conjugation efficiency

KW - cholehepatic shunting

KW - cholestasis

KW - primary biliary cirrhosis

KW - primary sclerosing cholangitis

KW - unconjugated bile acids

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0030003493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030003493&partnerID=8YFLogxK

U2 - 10.1016/0009-8981(95)06252-1

DO - 10.1016/0009-8981(95)06252-1

M3 - Article

C2 - 8740581

AN - SCOPUS:0030003493

VL - 248

SP - 175

EP - 185

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 2

ER -